A phase I/II study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.
Shaya J, Xie W, Saraiya B, Parikh M, Folefac E, Olson A, Choudhury A, Einstein D, Heath E, Parikh R, Kunos C, Ivy S, LoRusso P, Kurzrock R, Shapiro G, McKay R. A phase I/II study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress. Journal Of Clinical Oncology 2021, 39: tps182-tps182. DOI: 10.1200/jco.2021.39.6_suppl.tps182.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerPhase 2 componentCastration-resistant prostate cancerPhase 1 componentBone metastasesRadium-223PARP inhibitorsPrimary endpointOverall survivalProstate cancerPhase I/II studyRadiographic progression-free survivalFirst skeletal eventKey exclusion criteriaMore bone metastasesNon-bone metastasisPhase 2 doseStratification of responsePhase 1/2 studyPrior radiation therapyPhase 1/2 trialProgression-free survivalDose-escalation designTumor immune microenvironmentPlasma cell-free DNA